RankAlpha logo
Back to Rankings

XENE

XenonC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
View Chart
Current thesis
Xenon has materially de-risked azetukalner in epilepsy with a positive Phase 3 X-TOLE2 readout, stated an NDA timing target for Q3 2026, and bolstered liquidity through both ATM activity and the March 2026 upsized offering; that combination supports continued commercial-readiness work and broader pipeline execution [#PR-2026-03-09] [#PR-2026-03-12] [#10-K-2026-02-26].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +20.4.
What can break
Clinical read-through risk if later epilepsy or neuropsychiatry studies fail to match the strength of X-TOLE2.
Momentum
84
Value
41
Sentiment
34
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $58.00 · Bull $72.00 · Bear $42.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $80.80
Why
Momentum84 · Δ7d +20.4
Value41 · Δ7d -0.0
Sentiment34 · Δ7d +0.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
84
26% active weight
Current posture
7d trendImproving
Δ7d
+20.4
Δ21d
+28.0
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
34
34% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
-10.8
Why this grade

Composite grade C. Momentum 84.0 / Value 41.1 / Sentiment 33.6

Fundamentals (TTM)
As of 2026-07-22
Market Cap
$6.4B
Beta
0.96
Shares Out
96.67M
P/E (TTM) · Derived
-15.2
P/S (TTM)
430.58
P/FCF (TTM) · Derived
-17.54
Rev YoY
-100.0%
EPS YoY
+41.7%
Gross Margin
+66.1%
Op Margin
-4543.7%
Net Debt
-$540.94M
Current Ratio
27.79
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology